MAFA Antibody [N15J3] | Primary Antibodies

Application: Reactivity: Human, Mouse

Usage Information

Dilution
WB1:1000 IP1:200 IF1:1000 CHIP1:100

Application
WB, IP, IF, ChIP

Reactivity
Human, Mouse

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW Observed MW
37 kDa 195 kDa
^*Why do the predicted and actual molecular weights differ? The following reasons may explain differences between the predicted and actual protein molecular weight. Post-translational modifications(e.g., phosphorylation, glycosylation); Splice variants and isoforms; Relative charge; Multimerization.

Datasheet & SDS

Biological Description

Specificity
MAFA Antibody [N15J3] detects endogenous levels of total MAFA protein.

Clone
N15J3

Synonym(s)
hMafA; INSDM; MAF bZIP transcription factor A; MAFA; v-maf musculoaponeurotic fibrosarcoma oncogene homolog A (avian)

Background
MAFA, a member of the large MAF basic leucine-zipper transcription factor family, functions as a β cell–enriched regulator that confers tissue specificity and glucose responsiveness on the insulin gene and a broader set of β cell genes involved in stimulus–secretion coupling and hormone processing. The protein contains an N‑terminal transactivation domain that integrates glucose- and kinase-dependent regulatory inputs and a C‑terminal basic leucine-zipper region that mediates dimerization and binding to Maf recognition elements within cis-regulatory regions such as the C1/RIPE3b element of the insulin promoter, where MAFA acts in concert with PDX1 and NEUROD1 to drive β cell–selective transcription. Glucose regulates MAFA at both transcriptional and post-translational levels, with elevated glucose increasing MAFA expression and DNA-binding activity and with constitutive phosphorylation of multiple N‑terminal serine and threonine residues by glycogen synthase kinase 3 modulating protein stability so that changes in ambient glucose alter MAFA turnover and, in turn, insulin promoter occupancy. MAFA directly activates the insulin gene and also controls a network of β-cell genes central to insulin biosynthesis, metabolism-secretion coupling, and incretin responsiveness, including GLUT2, glucokinase, PDX1, NKX6.1, GLP1R, PCSK1, and pyruvate carboxylase, thereby coordinating glucose uptake, metabolic flux, proinsulin processing, and secretory capacity under physiological conditions. Expression of MAFA is largely restricted to insulin-producing β cells within adult islets, and the appearance of MAFA during the second wave of β cell differentiation marks the acquisition of mature β cell identity and robust insulin secretory function, while reduced MAFA levels accompany chronic hyperglycemia and β cell dysfunction in diabetic states. MAFA overexpression enhances insulin transcription, insulin content, and glucose-stimulated insulin secretion, whereas dominant-negative MAFA dampens these outputs and downregulates key β cell genes, indicating that MAFA sits near the top of a transcriptional hierarchy that maintains the mature β cell phenotype and preserves secretory performance under metabolic load. MAFA also participates in β cell reprogramming strategies, where its coexpression with PDX1 and NEUROD1 efficiently induces insulin biosynthesis in non–β cells and promotes conversion of islet α cells and progenitors toward a β cell–like state, linking this factor mechanistically to lineage specification and plasticity within the islet endocrine compartment. Germline or functional alterations in MAFA and its regulatory phosphosites associate with impaired insulin gene expression, β cell failure, and monogenic diabetes phenotypes, and MAFA downregulation is a consistent molecular feature of human type 2 diabetic islets.

Background

MAFA, a member of the large MAF basic leucine-zipper transcription factor family, functions as a β cell–enriched regulator that confers tissue specificity and glucose responsiveness on the insulin gene and a broader set of β cell genes involved in stimulus–secretion coupling and hormone processing. The protein contains an N‑terminal transactivation domain that integrates glucose- and kinase-dependent regulatory inputs and a C‑terminal basic leucine-zipper region that mediates dimerization and binding to Maf recognition elements within cis-regulatory regions such as the C1/RIPE3b element of the insulin promoter, where MAFA acts in concert with PDX1 and NEUROD1 to drive β cell–selective transcription. Glucose regulates MAFA at both transcriptional and post-translational levels, with elevated glucose increasing MAFA expression and DNA-binding activity and with constitutive phosphorylation of multiple N‑terminal serine and threonine residues by glycogen synthase kinase 3 modulating protein stability so that changes in ambient glucose alter MAFA turnover and, in turn, insulin promoter occupancy. MAFA directly activates the insulin gene and also controls a network of β-cell genes central to insulin biosynthesis, metabolism-secretion coupling, and incretin responsiveness, including GLUT2, glucokinase, PDX1, NKX6.1, GLP1R, PCSK1, and pyruvate carboxylase, thereby coordinating glucose uptake, metabolic flux, proinsulin processing, and secretory capacity under physiological conditions. Expression of MAFA is largely restricted to insulin-producing β cells within adult islets, and the appearance of MAFA during the second wave of β cell differentiation marks the acquisition of mature β cell identity and robust insulin secretory function, while reduced MAFA levels accompany chronic hyperglycemia and β cell dysfunction in diabetic states. MAFA overexpression enhances insulin transcription, insulin content, and glucose-stimulated insulin secretion, whereas dominant-negative MAFA dampens these outputs and downregulates key β cell genes, indicating that MAFA sits near the top of a transcriptional hierarchy that maintains the mature β cell phenotype and preserves secretory performance under metabolic load. MAFA also participates in β cell reprogramming strategies, where its coexpression with PDX1 and NEUROD1 efficiently induces insulin biosynthesis in non–β cells and promotes conversion of islet α cells and progenitors toward a β cell–like state, linking this factor mechanistically to lineage specification and plasticity within the islet endocrine compartment. Germline or functional alterations in MAFA and its regulatory phosphosites associate with impaired insulin gene expression, β cell failure, and monogenic diabetes phenotypes, and MAFA downregulation is a consistent molecular feature of human type 2 diabetic islets.

References
https://pubmed.ncbi.nlm.nih.gov/17149590/ https://pubmed.ncbi.nlm.nih.gov/12368292/

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%